Our top pick for
Penumbra Inc is a medical devices business based in the US. Penumbra shares (PEN) are listed on the NYSE and all prices are listed in US Dollars. Penumbra employs 3,300 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$278.19|
|52-week range||$163.49 - $315.00|
|50-day moving average||$271.75|
|200-day moving average||$270.08|
|Wall St. target price||$324.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.43|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-18)||4.68%|
|1 month (2021-09-23)||-1.56%|
|3 months (2021-07-27)||6.49%|
|6 months (2021-04-27)||-8.08%|
|1 year (2020-10-27)||16.48%|
|2 years (2019-10-25)||76.39%|
|3 years (2018-10-26)||101.66%|
|5 years (2016-10-27)||330.63%|
Valuing Penumbra stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Penumbra's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Penumbra's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 649x. In other words, Penumbra shares trade at around 649x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Penumbra's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $33.1 million.
The EBITDA is a measure of a Penumbra's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$671.4 million|
|Operating margin TTM||3.02%|
|Gross profit TTM||$356.6 million|
|Return on assets TTM||1.5%|
|Return on equity TTM||1.85%|
|Market capitalisation||$10.4 billion|
TTM: trailing 12 months
There are currently 1.7 million Penumbra shares held short by investors – that's known as Penumbra's "short interest". This figure is 4.8% up from 1.7 million last month.
There are a few different ways that this level of interest in shorting Penumbra shares can be evaluated.
Penumbra's "short interest ratio" (SIR) is the quantity of Penumbra shares currently shorted divided by the average quantity of Penumbra shares traded daily (recently around 181625.96858639). Penumbra's SIR currently stands at 9.55. In other words for every 100,000 Penumbra shares traded daily on the market, roughly 9550 shares are currently held short.
However Penumbra's short interest can also be evaluated against the total number of Penumbra shares, or, against the total number of tradable Penumbra shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Penumbra's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Penumbra shares in existence, roughly 50 shares are currently held short) or 0.0596% of the tradable shares (for every 100,000 tradable Penumbra shares, roughly 60 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Penumbra.
Find out more about how you can short Penumbra stock.
We're not expecting Penumbra to pay a dividend over the next 12 months.
Penumbra's shares were split on a 10:1 basis on 15 November 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 10 shares. This wouldn't directly have changed the overall worth of your Penumbra shares – just the quantity. However, indirectly, the new 90% lower share price could have impacted the market appetite for Penumbra shares which in turn could have impacted Penumbra's share price.
Over the last 12 months, Penumbra's shares have ranged in value from as little as $163.49 up to $315. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Penumbra's is 0.3159. This would suggest that Penumbra's shares are less volatile than average (for this exchange).
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States, Europe, Canada, Australia, and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; immersive virtual reality and display system that displays and tracks upper-extremity rehabilitation exercises under the REAL Immersive System brand name; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand name, as well as a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and POD Packing Coil brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.